Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global COVID-19 Access Program Facing ‘Financial Crisis’

Executive Summary

ACT-A, an initiative led by the World Health Organization and involving international health agencies, has significantly improved access to COVID-19 medical countermeasures in lower-income countries. However, further progress could be hindered by a funding shortfall, and ACT-A has urged donors to contribute their fair share.

You may also be interested in...



Coronavirus Notebook: Global COVID-19 Summit To Press For More Funding For Vaccines & Treatments, WHO Calls For End To IP Waiver ‘Stalemate’

CEPI has announced funding for a “variant-proof” vaccine being developed by a multidisciplinary consortium. The European Medicines Agency's new committee on drug shortages in health crises has held its first meeting, and the European Parliament’s new COVID-19 committee will quiz the health commissioner on the EU’s vaccines strategy and response to the pandemic.

WHO Backs Pfizer’s Paxlovid For High-Risk COVID-19 Patients

An international group of experts has issued new guidance on the use of therapeutics in patients with non-severe COVID-19.

New Zealand Hikes Fees To Reflect Changes In Drug Applications

Following a consultation last year, Medsafe has set new fee levels that take account of both cost-recovery principles and a 4.2% increase in the consumer price index. 

Topics

UsernamePublicRestriction

Register

PS146080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel